Structural Modification and Anti-inflammatory Evaluation of Deep-Sea-Derived Cycloheptapeptide Derivatives against Inflammatory Bowel Disease via NLRP3 Inflammasome Signaling Suppression
Journal of Natural Products · 03.11.2026
DOI: 10.1021/acs.jnatprod.6c01028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Natural Products, online erschienen am 03.11.2026. Verfasst von Yan-Wei Wu und 9 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Qingdao Postdoctoral Science Foundation, Hainan Provincial Department of Science and Technology, Postdoctoral Innovation Project of Shandong Province.
Abstract (Originalsprache)
The NLRP3 inflammasome plays a central role in the innate immune response of inflammatory bowel disease (IBD), and its excessive activation drives the release of pro-inflammatory cytokines and compromises intestinal mucosal barrier integrity. In this study, the natural cycloheptapeptide unguisin E (1) was identified through anti-inflammatory screening of a marine-derived molecule library. To improve its anti-inflammatory potency, 1 was employed as a lead compound for structural modification at the C-2 position of the indole moiety via Suzuki coupling, affording a series of cycloheptapeptide derivatives (2−40). Among them, CHNQD-01024 (12) significantly inhibited IL-1β release from the NLRP3 inflammasome in THP-1 and J774A.1 cell lines at 0.4 μM, exhibiting inhibition potency comparable to the positive control MCC950 at 2 μM. In the DSS-induced colitis mouse model, CHNQD-01024 significantly ameliorated systemic inflammation, mitigated colonic tissue damage, and restored intestinal barrier function at doses of 5−15 mg/kg, with efficacy comparable to the first-line clinical drug 5-ASA at 50 mg/kg. Mechanistic studies showed that CHNQD-01024 suppressed NLRP3 inflammasome-associated inflammatory signaling, accompanied by the inhibition of NF-κB signaling and ROS production, reduced NLRP3 expression, and impaired ASC oligomerization. Taken together, these findings identify CHNQD-01024 as a promising marine fungal-derived anti-inflammatory lead suppressing NLRP3 inflammasome-associated signaling.
Förderung
- Qingdao Postdoctoral Science Foundation
- Hainan Provincial Department of Science and Technology
- Postdoctoral Innovation Project of Shandong Province
- Key Laboratory of Tropical Medicinal Resource Chemistry, Ministry of Education
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Wu, Y., Kang, J., Chen, L., Sheng, W., Zhou, T., Chang, Q., Xing, Q., Wei, M., Liu, J., & Shao, C. (2026). Structural Modification and Anti-inflammatory Evaluation of Deep-Sea-Derived Cycloheptapeptide Derivatives against Inflammatory Bowel Disease via NLRP3 Inflammasome Signaling Suppression. Journal of Natural Products. https://doi.org/10.1021/acs.jnatprod.6c01028
Vancouver
Wu Y, Kang J, Chen L, Sheng W, Zhou T, Chang Q, et al. Structural Modification and Anti-inflammatory Evaluation of Deep-Sea-Derived Cycloheptapeptide Derivatives against Inflammatory Bowel Disease via NLRP3 Inflammasome Signaling Suppression. Journal of Natural Products. 2026. doi:10.1021/acs.jnatprod.6c01028
BibTeX
@article{Wu2026,
author = {Wu, Yan-Wei and Kang, Jia-Qi and Chen, Lu and Sheng, Wei-Hao and Zhou, Tian-Yi and Chang, Qian and Xing, Qian and Wei, Mei-Yan and Liu, Jian-Yu and Shao, Chang-Lun},
title = {Structural Modification and Anti-inflammatory Evaluation of Deep-Sea-Derived Cycloheptapeptide Derivatives against Inflammatory Bowel Disease via NLRP3 Inflammasome Signaling Suppression},
journal = {Journal of Natural Products},
year = {2026},
doi = {10.1021/acs.jnatprod.6c01028}
}
EUVIMED